Google and Perceptra, a Google technology licensing partner, are joining forces to provide AI-powered diabetic-retinopathy (DR) screening to around 1 million people in underserved communities across ...

The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the ...

Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.

AI has quietly revolutionized the field of ophthalmology.While the concept of AI may evoke futuristic images of robots and automation, the reality is that many of us have been integrating AI into our ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.

Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on whether ...